gsk-598809

GSK598809 is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans.

GSK-598809 L-tartrate sesquihydrate is an acute D3 antagonist.

GSK-598809 L-tartrate is an acute D3 antagonist.

(-)-GSK598809 is an isomer of GSK598809 that is a potent and selective antagonist of dopamine D3 Receptor.

Eucatropine, an anticholinergic agent, acts as a potent inhibitor of the muscarinic acetylcholine receptor (mAChR) with an IC 50 value of 0.583 μM.

(-)-GSK598809 hydrochloride is the isomer of GSK598809. GSK598809 is a selective antagonist of the dopamine D3 receptor (DRD3), which is a neural response that selectively enhances reward anticipation in drug and alcohol dependence during monetary policy and may repair reward deficits in substance dependence.

TZP-102 is a potent, oral, ghrelin receptor agonist that has been shown to improve diabetic gastroparesis symptoms.

Aspafilioside B is a steroidal saponin extracted from Asparagus filicinus that inhibits the growth and proliferation of HCC cell lines.